Literature DB >> 29569128

Letter to the Editor.

Rajat Dhar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29569128      PMCID： PMC6082640          DOI： 10.1007/s12028-018-0517-9

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN： 1541-6933            Impact factor:   3.210


× No keyword cloud information.
  6 in total

1.  Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage : a randomized controlled trial.

Authors:  L Lennihan; S A Mayer; M E Fink; A Beckford; M C Paik; H Zhang; Y C Wu; L M Klebanoff; E C Raps; R A Solomon
Journal:  Stroke       Date:  2000-02       Impact factor: 7.914

2.  Effect of High-Dose Simvastatin on Cerebral Blood Flow and Static Autoregulation in Subarachnoid Hemorrhage.

Authors:  Michael N Diringer; Rajat Dhar; Michael Scalfani; Allyson R Zazulia; Michael Chicoine; William J Powers; Colin P Derdeyn
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

3.  RBC Transfusion Improves Cerebral Oxygen Delivery in Subarachnoid Hemorrhage.

Authors:  Rajat Dhar; Allyson R Zazulia; Colin P Derdeyn; Michael N Diringer
Journal:  Crit Care Med       Date:  2017-04       Impact factor: 7.598

4.  Unilateral posterior reversible encephalopathy syndrome with hypertensive therapy of contralateral vasospasm: case report.

Authors:  Rajat Dhar; Ralph Dacey; Theresa Human; Gregory Zipfel
Journal:  Neurosurgery       Date:  2011-11       Impact factor: 4.654

5.  Effects of iso- and hypervolemic hemodilution on regional cerebral blood flow and oxygen delivery for patients with vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  A Ekelund; P Reinstrup; E Ryding; A-M Andersson; T Molund; K-A Kristiansson; B Romner; L Brandt; H Säveland
Journal:  Acta Neurochir (Wien)       Date:  2002-07       Impact factor: 2.216

6.  Effect of HHH-Therapy on Regional CBF after Severe Subarachnoid Hemorrhage Studied by Bedside Xenon-Enhanced CT.

Authors:  Henrik Engquist; Elham Rostami; Elisabeth Ronne-Engström; Pelle Nilsson; Anders Lewén; Per Enblad
Journal:  Neurocrit Care       Date:  2018-04       Impact factor: 3.210
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.